Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Biotechnology

Healthcare
$6.77 +1.96%

+$0.19 today

Market cap
$68.98M
Beta
0.11
P/E (TTM)
-14.7
EPS (TTM)
-$0.67
52W Low $3.92High $19.15

Volume 0.02M

Average 1.40M

ATRA Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Atara Biotherapeutics, Inc.NASDAQ: ATRA

Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Free cash flow declines year over year

Q1 FY2026 free cash flow of $3.07M (cash outflow) fell 89.1% year over year, behind the -61.6% change in trailing-twelve-month free cash flow. Sequentially, it fell 46.1% from the prior quarter. Over 3 fiscal years it compounded at -43.0% a year.

Context

  • Free cash flow amounted to 42.2% of revenue in FY2025, down 11.3 pp from a year earlier.
  • Free cash flow grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -89.1% toward the trailing-twelve-month pace of -61.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$3.07M-46.1% QoQ
Last fiscal yearDec 2025
-$50.94M-26.1% YoY
LTMMar 2026
-$25.88M-61.6% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-89.1%——
1 year-26.1%——
3-year CAGR-43.0%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(50.94M) USD
Year-over-year change
+26.1%

Free Cash Flow vs competitors

How ATRA compares with its peers on the latest reported figures

  • Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -61.6% is the lowest of 11, against a peer median of -11.5%.
  • Free cash flow amounts to 111.8% of revenue for ATRA, versus a peer median of 383.5%.
ATRA Competitors
Free Cash Flow for ATRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$152.14M USD-23.4%+246.3%152.7%
MGNXMacroGenics, Inc.LTM Mar 2026$71.69M USD-1.0%-2.9%45.6%
OVIDOvid Therapeutics Inc.LTM Mar 2026$41.95M USD-15.4%-12.2%589.1%
STTKShattuck Labs, Inc.LTM Mar 2026$41.28M USD-26.9%-27.8%4128.2%
CNTXContext Therapeutics Inc.LTM Mar 2026$32.82M USD+115.0%+23.3%—
IFRXInflaRx N.V.LTM Mar 2026€28.93M EUR-39.4%+0.1%98624.1%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$25.88M USD-61.6%-43.0%111.8%
CLNNClene Inc.LTM Mar 2026$18.1M USD-6.0%-25.1%13509.0%
COYACoya Therapeutics, Inc.LTM Mar 2026$14.12M USD-7.5%+14.0%177.9%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$8.74M USD-16.5%-27.6%—
CSBRChampions Oncology, Inc.LTM Jan 2026$3.82M USD+388.4%+19.4%6.6%
Peer median (excluding ATRA) —-11.5%-1.4%383.5%

Competitors are the stored peer set for ATRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(340.14M)(228.3M)(276.13M)(85.4M)32.69M
Depreciation & Amortization9.35M5.65M4.83M5.05M2.38M
Deferred Income Tax1.79M0000
Stock-Based Compensation53.87M53.84M45.39M27M9.75M
Change in Working Capital52.58M(61.47M)15.34M(30.96M)(104.74M)
Accounts Receivables264K(39.24M)6.11M32.63M229K
Inventory3.34M(1.59M)(8.12M)(4.43M)10.66M
Accounts Payables9.07M(9.21M)(3.13M)687K(4.24M)
Other Working Capital39.91M(11.44M)20.48M(59.84M)(111.38M)
Other Non-Cash Items2.04M(40.15M)17.59M15.59M8.98M
Operating Cash Flow(220.52M)(270.43M)(192.98M)(68.72M)(50.94M)
Capital Expenditures(10.58M)(4.19M)(1.22M)(246K)0
Acquisitions (Net)(32.84M)000948K
Purchases of Investments(301.13M)(180.59M)(83.65M)(19.67M)(7.89M)
Sales of Investments333.97M292.97M208.71M28.54M25.09M
Other Investing Activities32.84M94.77M25K00
Investing Cash Flow22.26M202.96M123.87M8.62M18.15M
Debt Repayment(254K)(518K)(947K)(892K)(250K)
Common Stock Issued98.7M21.89M2.14M59.95M16.35M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities5.5M31.71M821K223K(1K)
Financing Cash Flow103.94M53.08M2.01M59.28M16.1M
Effect of Forex Changes00000
Net Change in Cash(94.32M)(14.39M)(67.1M)(811K)(16.69M)
Free Cash Flow(231.1M)(274.62M)(194.2M)(68.96M)(50.94M)

Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Intrinsic Alpha fair value

Locked

Current Price

$6.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.